CytoDyn (OTCMKTS:CYDY) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.01), Bloomberg Earnings reports.

Shares of CYDY stock opened at $0.53 on Thursday. The firm has a market capitalization of $133.15 million, a P/E ratio of -1.83 and a beta of 0.37. CytoDyn has a one year low of $0.40 and a one year high of $0.84.

CYDY has been the topic of a number of research reports. HC Wainwright set a $2.00 price objective on CytoDyn and gave the company a “buy” rating in a research report on Wednesday. Zacks Investment Research upgraded CytoDyn from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research report on Tuesday, September 18th.

CytoDyn Company Profile

CytoDyn Inc, a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease.

See Also: Buyback

Earnings History for CytoDyn (OTCMKTS:CYDY)

Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with's FREE daily email newsletter.